IMPORTANCE Enzyme-linked immunosorbent assay (ELISA) and/or chemiluminescent enzyme immunoassay (CLEIA) for BP180 noncollagenous 16A (NC16A) extracellular domain is a sensitive diagnostic tool for bullous pemphigoid (BP). However, some patients with BP have negative results for these assays.
A mong autoantibody-induced autoimmune diseases, 1 bullous pemphigoid (BP) is characterized by tense blisters and edematous erythemas, with the highest prevalence and susceptibility in elderly individuals. Immunologically, BP is characterized by circulating antibasement membrane zone (BMZ) antibodies. Their targets are mainly the 230-kD-protein BP antigen 1 (BPAG1, BP230) and the 180-kD-protein BP antigen 2 (BPAG2, BP180, also known as type XVII collagen). An extracellular domain of BP180, the noncollagenous 16A (NC16A) domain contains the main epitope targeted in BP. Anti-BP180 NC16A are pathogenic; they reduce BP180 on the surface of keratinocytes via macropinocytosis and induce complement and neutrophil activation through the Fc gamma receptor, which results in blister formation. 2, 3 Enzyme-linked immunosorbent assay (ELISA)
for anti-BP180 NC16A is available and is useful for diagnosis and disease monitoring. 4 Recently, a chemiluminescent enzyme immunoassay (CLEIA) was developed, which is a highly effective autoantibody detection system that is as reliable as ELISA. 5 However, a small number of patients with BP have negative results for BP180 NC16A in these assays (hereafter referred to as non-NC16A patients with BP). The characteristics of non-NC16A patients with BP have not been well described, although a few studies have been reported. 6, 7 In this study, we analyzed patients with BP in our department and summarized their immunological and clinical features.
Methods

Patients
A total of 152 patients with BP who visited the Kurume University Hospital between January 2007 and September 2016 were enrolled in this study. The study was approved by the ethics committee of the Kurume University and was performed in adherence with the Declaration of Helsinki Guidelines. All participants provided written informed consent and they were not compensated. Thirty-one NC16A-positive patients with BP and all the 14 non-NC16A patients with BP were evaluated including their disease severity with the BP Disease Area Index (BPDAI). Detailed information is provided in eMethods in the Supplement.
Results
Of the 152 patients with BP, 14 had negative results for BP180 NC16A on ELISA or CLEIA during their first visit to our hospital. The clinical and immunological features of non-NC16A patients with BP are summarized in the eTable in the Supplement. We evaluated the disease severity using the BPDAI scores. Scores for cutaneous erosions/blister and urticaria/erythema were significantly lower in non-NC16A patients with BP: Non-NC16A patients with BP vs NC16A-positive patients with BP (mean [ Figure 1 .
We then tested the patients' sera for immunoreactivity to outside of NC16A and for other components at the epidermal BMZ using immunofluorescence, western blotting (WB) and BP230 ELISA, which are well established in our department. 8 Western blotting analyses revealed that epidermal extracts were positive for the 180-kD protein in 2 patients, indicating the reactivity to BP180; for the 190-kD protein in 2 patients, indicating the reactivity to periplakin and for the 230-kD protein in 3 patients, indicating the reactivity to BP230. No patients exhibited reactivity to the recombinant BP180 NC16A protein. Ten and 3 patients exhibited reactivity to LAD-1 in HaCaT cell supernatant and the recombinant BP180 C-terminal domain protein, respectively. Results of ELISA revealed that 7 patients were positive for BP230 ( Figure 2 ). Because non-NC16A patients with BP had milder phenotypes, we also analyzed their responses to treatment. Consistent with the low BPDAI scores, 5 (35.7%) patients did not require any systemic corticosteroids and the others required a dose of prednisolone at less than 30 mg per day.
Izumi et al 7 reported that non-NC16A patients with BP exhibited less erythema and had a high prevalence of administration of DPP4i. In our non-NC16A patients with BP, 3 (21.4%) were administered DPP4i before disease onset; however, we could not confirm the duration and end of DPP4i administration. It remains unclear how autoimmunity causes the recognition of BP180 NC16A during BP course. Di Zenzo et al 9 analyzed the time course of reactivity to the epitopes of BP180 and BP230. In this study, we analyzed the time course of reactivity to NC16A as detected by BP180 ELISA and/or CLEIA. The mean (SD) duration of follow-up to this reactivity was 31.9 (33.2) (range, 0 to 108) weeks. In all the 14 patients, BP180 ELISA and/or CLEIA results remained negative.
Key Points
Question What is the clinical and immunological phenotype in patients with bullous pemphigoid (BP) who are negative for BP180 noncollagenous 16A (NC16A) domain in enzyme-linked immunosorbent assay (ELISA) and/or chemiluminescent enzyme immunoassay (CLEIA)?
Findings Our retrospective study revealed that patients who had negative results on these assays presented with milder phenotypes and less erythema and required less extensive treatments. The reactivity to NC16A domain rarely became positive during the later stages of the disease.
Meaning Nonreactivity of IgG to the NC16A domain may predict a mild disease course.
Discussion
We report 14 patients who were negative for BP180 NC16A ELISA and/or CLEIA during their first visit to our hospital. These patients had relatively milder disease and fewer erythemas than those with the usual BP type and required lower systemic corticosteroid treatments along with a good response to the treatment. 10 Recently, Izumi et al 7 reported the features of non-NC16A patients with BP using a newly developed full-length eukaryotic BP180 ELISA, and these patients had relatively mild inflammation (erythema) compared with NC16A-positive patients with BP. We also observed similar features in non-NC16A patients with BP. The BP180 NC16A ELISA correlates with disease severity, 4 and pathogenicity of anti-NC16A IgG has been demonstrated in vivo. 11 Based on these reports, we suggest that anti-NC16A IgG is associated with the major pathogenicity and non-NC16A BP is a milder form of the disease. Imafuku et al 12 reported that autoantibodies targeting the regions outside of NC16A depleted BP180 on keratinocytes, although their capacity was lower than that of NC16A autoantibodies in vitro, which may be related to the mild phenotype of non-NC16A BP. Recently the pathogenicity of anti-BP180 IgE was characterized. 13 In non-NC16A patients with BP, anti-BP180 IgE may be pathogenic. Our results suggest that recognition of outside of NC16A rarely spreads to NC16A in patients with BP. Di Zenzo et al 9 reported that no patients developed reactivity to NC16A (P490) later during the disease course. Studies on mice conducted by the same group revealed similar tendencies.
14 Our results suggest that recognition of NC16A by the humoral immune system occurs during the early stage of the disease in most patients, whereas epitope spreading to NC16A rarely occurs in patients without anti-NC16A IgG. In the study by Izumi et al 7 DDP4i was administered to 7 of 14 non-NC16A patients with BP, and they suggested that DPP4i is involved in the development of non-NC16A BP. They used full-length BP180 and focused on patients who had reactions only with BP180 other than with NC16A, whereas our analysis contained anti-BP230 antibodies alone-positive cases. If we exclude patients with anti-BP230 solely from non-NC16A patients with BP, 3 (30.0%) of 10 non-NC16A patients with BP and 19 (13.8%) of 138 NC16A-positive patients with BP were administrated DPP4i before the disease onset; this was still not significant (P = .17). This discrepancy may be owing to 
Limitations
This study included a small number of non-NC16A patients with BP, particularly non-NC16A-DPP4i-related BP patients. This was a single-center case series.
Conclusions
We report 14 non-NC16A patients with BP and characterized their unique features, including few erythemas, mild phenotypes, and no epitope spreading to NC16A during the later stages of the disease. The BP180 NC16A ELISA and/or CLEIA is useful for the diagnosis of BP. However, clinicians should keep in mind that some patients with BP exhibit no reactivity in these assays and have unique clinical and immunological features. The complete characterization of non-NC16A BP including with DPP4i administration requires the accumulation of more cases and further investigations. 
BP disease area index
Thirty-one patients who were selected randomly from NC16A-BP and all 14 patients in Non-NC16A BP were scored the BP disease area index (BPDAI) 2 by three dermatologists using clinical pictures taken during the patients' first visit. Disease severity based on the BPDAI score was classified according to the guideline for management of pemphigoid by the Japanese dermatological association (published on The Japanese journal of dermatology 2017; 127: 1483-1521, described in Japanese). Scoring for skin erosions/blisters was mild ≤ 14, 15 ≤ moderate ≤ 34 and severe ≥ 35; that for skin urticarial/erythema was mild ≤ 19, 20 ≤ moderate ≤ 34 and severe ≥ 35 and that for mucosal erosions/blisters was mild ≤ 9, 10 ≤ moderate ≤ 24 and severe ≥ 25. The highest severity from among the three items was considered as the severity of each patient.
ELISA/CLEIA
For the detection of the reactivity to BP180NC16A, MESACUP BP180 ELISA kits (MBL Co, Nagoya, Japan) were used according to the manufacturer's instructions. After 6 December 2013, some patients' sera were tested by CLEIA using the STACIA MEBLux test for BP180. For all patients tested with the ELISA/CLEIA, sera collected during their first visit to our hospital were tested by SRL, Inc. (Tokyo, Japan).
Westernblotting (WB)
WB analyses with normal human epidermal 3 and dermal 4 extracts, concentrated supernatant from HaCaT cell cultures 5, 6 and recombinant BP180NC16A 7 and BP180 C-terminal 8 domain proteins were performed as previously described using 1:20 dilutions of patients sera for IgG and 1:10 for IgA. For the preparation of dermal extract, 2 mM EDTA and 1 mM PMSF containing PBS for 48 h was used instead of 1 M Concentrated supernatant from HaCaT cell cultures were used for detecting the reactivity to a 120-kD protein called LAD-1, which is a truncated version of the extracellular domain of BP180.
10
Immunofluorescence (IF)
Direct IF (DIF) was performed using perilesional skin specimens from each patient as described previously. 11 Indirect IF (IIF) using normal human skin and 1 M NaCl-split-normal human skin (ss-IIF)
were performed as described previously.
12,13
Statistical analysis
Data are presented as mean ± SD. Statistical analysis of prevalence of DPP4i administration in NC16A-positive BP and Non-NC16A BP was analysed using the Fisher's exact test. Statistical analysis of BPDAI between both groups was performed using Mann-Whitney test. All statistical analyses were performed using GraphPad Prism (Version 6.05; GraphPad Software, San Diego, CA). A p-value of 0.05 was considered statistically significant. 
